StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$34.42−1.49 (-4.15%)

Close on Nov 18, 2026Market cap $1.18BP/E –Yield –

Nektar Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Nektar Therapeutics's operating cash flow for the twelve months ending Dec 31, 2025 was -$208.51M. For fiscal 2025 it was -$208.51M. The highest annual figure on record is $718.21M in fiscal 2018.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$208.51M–
FY2024Dec 31, 2024-$175.71M–
FY2023Dec 31, 2023-$192.61M–
FY2022Dec 31, 2022-$304.01M–
FY2021Dec 31, 2021-$412.66M–
FY2020Dec 31, 2020-$313.29M–
FY2019Dec 31, 2019-$328.68M-145.8%
FY2018Dec 31, 2018$718.21M–
FY2017Dec 31, 2017-$80.41M–
FY2016Dec 31, 2016-$117.02M–
FY2015Dec 31, 2015-$73.08M–
FY2014Dec 31, 2014-$142.01M–
FY2013Dec 31, 2013-$38.53M–
FY2012Dec 31, 2012-$129.76M–
FY2011Dec 31, 2011-$113.74M–
FY2010Dec 31, 2010-$55.87M-240.6%
FY2009Dec 31, 2009$39.74M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$64.96M–
Q3 FY2025Sep 30, 2025-$48.76M–
Q2 FY2025Jun 30, 2025-$45.74M–
Q1 FY2025Mar 31, 2025-$49.05M–
Q4 FY2024Dec 31, 2024-$46.19M–
Q3 FY2024Sep 30, 2024-$43.93M–
Q2 FY2024Jun 30, 2024-$37.70M–
Q1 FY2024Mar 31, 2024-$47.89M–
Q4 FY2023Dec 31, 2023-$47.05M–
Q3 FY2023Sep 30, 2023-$42.12M–
Q2 FY2023Jun 30, 2023-$51.52M–
Q1 FY2023Mar 31, 2023-$51.92M–
Q4 FY2022Dec 31, 2022-$57.70M–
Q3 FY2022Sep 30, 2022-$82.89M–
Q2 FY2022Jun 30, 2022-$74.99M–
Q1 FY2022Mar 31, 2022-$88.42M–
Q4 FY2021Dec 31, 2021-$151.54M–
Q3 FY2021Sep 30, 2021-$101.14M–
Q2 FY2021Jun 30, 2021-$82.90M–
Q1 FY2021Mar 31, 2021-$77.09M–
Q4 FY2020Dec 31, 2020-$98.63M–
Q3 FY2020Sep 30, 2020-$52.68M–
Q2 FY2020Jun 30, 2020-$83.90M–
Q1 FY2020Mar 31, 2020-$78.08M–
Q4 FY2019Dec 31, 2019-$125.22M–
Q3 FY2019Sep 30, 2019-$68.64M–
Q2 FY2019Jun 30, 2019-$53.92M-105.6%
Q1 FY2019Mar 31, 2019-$80.90M–
Q4 FY2018Dec 31, 2018-$117.55M–
Q3 FY2018Sep 30, 2018-$71.41M-176.7%
Q2 FY2018Jun 30, 2018$959.64M–
Q1 FY2018Mar 31, 2018-$52.47M–
Q4 FY2017Dec 31, 2017-$80.40M–
Q3 FY2017Sep 30, 2017$93.08M–
Q2 FY2017Jun 30, 2017-$58.52M–
Q1 FY2017Mar 31, 2017-$34.57M–
Q4 FY2016Dec 31, 2016-$52.41M–
Q3 FY2016Sep 30, 2016-$27.36M–
Q2 FY2016Jun 30, 2016-$13.60M–

More Nektar Therapeutics figures

See a number that looks wrong?